CN115212130A - Composition with anti-wrinkle repair effect and low discoloration possibility - Google Patents
Composition with anti-wrinkle repair effect and low discoloration possibility Download PDFInfo
- Publication number
- CN115212130A CN115212130A CN202210733199.3A CN202210733199A CN115212130A CN 115212130 A CN115212130 A CN 115212130A CN 202210733199 A CN202210733199 A CN 202210733199A CN 115212130 A CN115212130 A CN 115212130A
- Authority
- CN
- China
- Prior art keywords
- composition
- wrinkle
- fructo
- fucosyllactose
- oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 230000000694 effects Effects 0.000 title claims abstract description 27
- 230000001153 anti-wrinkle effect Effects 0.000 title claims abstract description 26
- 230000008439 repair process Effects 0.000 title claims abstract description 15
- 238000002845 discoloration Methods 0.000 title claims abstract description 8
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 23
- 229930091371 Fructose Natural products 0.000 claims abstract description 17
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 17
- 239000005715 Fructose Substances 0.000 claims abstract description 17
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 17
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 17
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims abstract description 15
- MLIKYFGFHUYZAL-UHFFFAOYSA-K trisodium;hydron;phosphonato phosphate Chemical compound [Na+].[Na+].[Na+].OP([O-])(=O)OP([O-])([O-])=O MLIKYFGFHUYZAL-UHFFFAOYSA-K 0.000 claims abstract description 15
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940094944 saccharide isomerate Drugs 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 235000020256 human milk Nutrition 0.000 claims description 14
- 210000004251 human milk Anatomy 0.000 claims description 14
- 230000008859 change Effects 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 229940062827 2'-fucosyllactose Drugs 0.000 claims description 11
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims description 11
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims description 11
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims description 11
- 229920001542 oligosaccharide Polymers 0.000 claims description 11
- 150000002482 oligosaccharides Chemical class 0.000 claims description 11
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 9
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 9
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 9
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 9
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 claims description 8
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims description 7
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims description 7
- 239000002131 composite material Substances 0.000 abstract description 6
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 abstract description 5
- 239000001177 diphosphate Substances 0.000 abstract description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract description 3
- 235000011180 diphosphates Nutrition 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 14
- 230000037303 wrinkles Effects 0.000 description 14
- 239000006071 cream Substances 0.000 description 13
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 6
- 238000013112 stability test Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 230000035618 desquamation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011076 safety test Methods 0.000 description 3
- 230000005808 skin problem Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000004383 yellowing Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- 229940025237 fructose 1,6-diphosphate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940125698 hormone suppressant Drugs 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 230000018448 secretion by cell Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a composition with anti-wrinkle repair efficacy and uneasy discoloration, which is characterized in that: the composite material comprises the following components in percentage by mass: 40-81.8% of saccharide isomerate, 10-25% of ribose, 0.2-5% of fructose diphosphate trisodium and 8-30% of fructo-oligosaccharide liquid. The composition prepared by the invention solves the technical problem that the trisodium fructo diphosphate is easy to yellow in an aqueous solution, has good color stability, is safe and mild, and has better anti-wrinkle and repair effects.
Description
Technical Field
The invention relates to the technical field of cosmetic preparation, in particular to a composition which has anti-wrinkle and repairing effects and is not easy to discolor.
Background
With the development of the cosmetic industry and the provision of new regulations on efficacy tests, a new raw material which is really effective, safe and mild is urgently needed to be discovered. At present, alcohol A is required to establish tolerance as a main anti-aging raw material, and the addition amount of the alcohol A is limited. Peptides are expensive and can only be added in trace amounts. Collagen has a large molecular weight and cannot be effectively absorbed through skin. Therefore, the development of a safe, mild and effective anti-wrinkle repair raw material has a wide market prospect.
Fructose diphosphate (Fructose-1, 6-diphosphate), FDP for short, is an intermediate product in the intracellular carbohydrate metabolism process, is a biochemical drug for improving the cell metabolism on the molecular level, has the functions of accumulating the concentration of high-energy phosphate substances in cells, promoting potassium ion backflow, recovering the polarization state of the cells, and facilitating the metabolism and utilization of glucose by the cells in the states of cell injury, anoxic shock and the like, repairing cell injury and the like. The fructose diphosphate trisodium is in a sodium salt form, is widely applied to acute treatment of acute myocardial infarction, myocardial ischemia, shock and the like, and can improve cell metabolism and repair cell injury in cosmetics, thereby having an anti-aging effect. However, trisodium fructodiphosphate is prone to yellowing in aqueous solution, and when the trisodium fructodiphosphate is directly added into cosmetics, stability, aesthetic property and product quality are affected, so that the trisodium fructodiphosphate cannot be widely applied.
Human Milk Oligosaccharides (HMOs) are one of 2 carbohydrates mainly contained in human milk. In studying the various compositional differences between human and bovine milk, one major difference was found to be the presence of HMOs in human milk, but not in bovine milk and infant formulas currently on the market. The oligosaccharide which is the most abundant in human milk is used as a component with a probiotic function in the breast milk, can regulate the environment of intestinal flora, promote the growth of beneficial flora, regulate the immune system and play an important role in promoting the development of the brain. The monomer 2' -fucosyllactose is found to inhibit Th17 cellular immune response and secretion of Th17 related cytokines and improve IMQ-induced psoriasis in the skin by regulating STAT3 signaling pathway. In addition, the research result shows that the 2' -fucosyllactose can reduce the over-expression of interleukins IL-6, IL-8 and IL-1 alpha, can resist the inflammation and stimulation caused by environmental pollution and can relieve the inflammatory aging.
D-ribose (alias hetero-dendrimer, ribofuranose) with molecular formula of C 5 H 10 O 5 The molar mass is 150.13g/moL, is an important component of nucleic acid, nucleotide, vitamin and various nucleotide coenzymes, and belongs to five-carbon sugar. D-ribose is reduced to form D-ribitol, which is an important monomer, composed teichoic acid is an important component of the cell wall of gram-positive bacteria, ribitol residues can also constitute riboflavin (VB 2) and flavin mononucleotide, and D-ribose usually runs together with phosphoric acid in organisms and has very important physiological action. With ageThe research proves that the D-ribose can improve the respiration of cells, generate new ATP, provide energy for the respiration of cells and have the effect of delaying skin aging.
Disclosure of Invention
The invention aims to solve the technical problem of providing a composition which has the effects of resisting wrinkles and repairing, has good color stability and is difficult to change color.
The composition with the anti-wrinkle repairing effect and the color not easy to change is characterized by comprising the following components in parts by weight: the composition consists of the following components: 40% -81.8% of saccharide isomerate, 10% -25% of ribose, 0.2% -5% of fructose diphosphate trisodium and 8% -30% of fructo-oligosaccharide solution; the sugar isomer contains more than 1% of human milk oligosaccharide, and the human milk oligosaccharide is one of 2' -fucosyllactose (2 ' -FL), 3-fucosyllactose (3-FL), lactose-N-tetraose (LNT), 3' -sialyllactose (3 ' -SL) and 6' -sialyllactose (6 ' -SL) or a mixture of the 2' -fucosyllactose (2 ' -FL), the 3-fucosyllactose (3-FL), the 3' -sialyllactose (LNT), the 3' -sialyllactose (3 ' -SL) and the 6' -sialyllactose (6 ' -SL), and the percentages are mass percentages.
The saccharide isomerate can be obtained by fermenting corn syrup, lactose and fucose by conventional processes using mixed strains of Lactobacillus fermentum, lactobacillus gasseri, lactobacillus salivarius, etc.
The 2 '-fucosyllactose (2' -FL), 3-fucosyllactose (3-FL), lacto-N-tetraose (LNT), 3 '-sialyllactose (3' -SL), 6 '-sialyllactose (6' -SL), or mixtures thereof are HMOs.
The ribose, CAS number 50-69-1, is numbered 02786 on the used cosmetic raw materials catalog (2021 edition);
the fructo-oligosaccharide solution is 35% of aqueous solution of fructo-oligosaccharide with mass concentration, and the CAS number of the fructo-oligosaccharide is 308066-66-2;
the trisodium fructose diphosphate, CAS No. 81028-91-3, is numbered 02700 on the catalogue of used cosmetic raw materials (2021 edition).
The invention also provides a preparation method of the composition with the anti-wrinkle repair effect and the uneasy color change, which is characterized by adopting the following steps:
A. weighing 40-81.8% of saccharide isomerate, 10-25% of ribose, 0.2-5% of fructose diphosphate trisodium and 8-30% of fructo-oligosaccharide solution according to the following mass percentage;
B. adding the saccharide isomerate, ribose, fructose diphosphate trisodium and fructo-oligosaccharide solution weighed in the step A into a stirring kettle, filling nitrogen for protection, and stirring at the rotating speed of 1200-2000rpm/min for 30-50 minutes until the mixture is uniformly mixed; homogenizing at 2800-3500rpm/min for 8-15 min to obtain syrup-like mixture, which is the composition with wrinkle removing and repairing effects.
The composition with the anti-wrinkle repair effect, which is prepared by the invention, adopts the saccharide isomerate, the ribose, the fructo-oligosaccharide and the fructose diphosphate trisodium which are prepared in a specific ratio, and has the advantages of safety, mildness, good anti-wrinkle effect and good repair effect, and the composition is not easy to turn yellow.
The invention has the following effective effects: the color is stable and is not easy to turn yellow; the mildness is good; the anti-wrinkle effect is good; the repairing effect is good.
The invention has carried out the following experiments:
1. stability test
Compositions were prepared according to the mass percentages of the substances shown in table 1, and examples 1-5 are compositions prepared according to the present technology for different substance content ratios.
Comparative example 1 is the same fructose diphosphate trisodium and ribose as in example 3, but without the saccharide isomerate.
Comparative example 2 is fructose diphosphate trisodium and the saccharide isomer in accordance with example 3, but without the addition of ribose.
Comparative example 3 is fructose diphosphate trisodium and saccharide isomer identical to example 3, but without addition of fructooligosaccharide solution.
The preparation methods of comparative example 1, comparative example 2 and comparative example 3 are the same as example 3.
TABLE 1 Mass percentages of substances in examples and comparative examples
The above samples were placed under 5 ℃, 45 ℃ and room temperature light conditions for stability test, and the color, appearance change and stability test results of the samples were measured at 2 weeks, 4 weeks, 8 weeks and 12 weeks, respectively, as shown in table 2.
TABLE 2 stability test results
". Smallcircle" indicates no discoloration.
From the test results of table 2, it can be seen that the compositions prepared according to the present invention have better stability and no discoloration in all examples after the stability test for 12 weeks, while the comparative examples have discoloration problems in the stability test. Therefore, the composition prepared by the invention has better light irradiation and high and low temperature color stability.
2. Safety test
35 healthy volunteers aged 18-60 years were selected and subjected to a mildness test according to the cosmetic safety technical Specification 2015 edition-human skin Patch test. According to GB 171492-1997 'diagnosis standard and treatment principle of cosmetic contact dermatitis', the subjects are confirmed to have no serious systemic diseases, no immunodeficiency or autoimmune diseases, no active allergic diseases, no allergic history to skin care cosmetics, no general use of hormones and immunosuppressants in 1 month, no pregnancy or lactation period and no ethical contraindication.
TABLE 3 composition of safety test sample creams
A cream was prepared according to the ingredients shown in table 3, and example 1 or 2 or 3 or 4 or 5 was added to the cream to obtain a corresponding test sample, which was then subjected to patch test. The plaque tester blank sample was a cream without the ingredients of example 1 or 2 or 3 or 4 or 5.
Placing the tested object about 0.020mL to 0.025mL in a spot tester by using a closed spot test method, externally applying a hypoallergenic adhesive tape on the back of the tested object, removing the tested object after 24 hours, and respectively observing skin reactions once in 0.5h,24h and 48 h. Recording reaction results according to grading standards, wherein grade 0 is negative reaction, grade 1 is suspicious reaction, only weak erythema exists, grade 2 is weak positive reaction, erythema, infiltration, edema can exist, pimple exists, grade 3 is strong positive reaction, erythema, infiltration, edema, pimple, herpes reaction can exceed a tested area, grade 4 is strong positive reaction, obvious erythema, severe infiltration, edema and fusional herpes, and the reaction exceeds the tested area. The results of the experiment are shown in table 4.
Table 4 safety test results
As can be seen from Table 4, the subjects in the patch test have no adverse reaction in the samples of the examples, which indicates that the composition prepared by the invention has the characteristic of good safety.
3. Anti-wrinkle efficacy test
To further prove the anti-wrinkle effect of the composition prepared by the invention, 70 healthy female volunteers aged 30-55 years are selected, the volunteers are required to have obvious wrinkles, and the volunteers are randomly divided into an experimental group and a control group, wherein 35 persons in each group are subjected to an anti-wrinkle effect test. The volunteers applied the cream of the sample of example 3 above to the cheek once in the morning and once in the evening, as required, and the control group used a blank sample of cream without added saccharide composition, the test requiring the volunteers to be predominantly mobile indoors during the test period, avoiding long-term unprotected exposure to sunlight. Before use, after 2,4,6,8 weeks, the canthus of the volunteer is selected as a test part, the number of wrinkles, the ratio of the area of the wrinkles and the average depth of the total wrinkles are detected by using a PROMIS LITE wrinkle measuring instrument of LMI Technologies, germany, the test data is averaged, and the wrinkle-resistant efficacy test results are shown in Table 5.
TABLE 5 anti-wrinkle efficacy test results
As can be seen from table 5, after 8 weeks of use, the number of wrinkles in the experimental group was reduced by 22.47%, the average ratio of the area of wrinkles was reduced by 27.89%, and the average depth of total wrinkles was reduced by 22.39%. According to the statistical result, after the test subjects use the face cream added with the composition which has the anti-wrinkle repairing efficacy and is not easy to discolor, the P value of the statistical result before and after the number of wrinkles, the area ratio of the wrinkles and the average depth of the total wrinkles is less than 0.05, and the statistical result is obvious. Therefore, the composition prepared by the invention has obvious anti-wrinkle effect.
4. Testing of repair effects
In order to further prove the repairing effect of the composition prepared by the invention, 70 healthy female volunteers aged 20-50 years are selected, the volunteers are required to have skin problems such as dry face, desquamation, redness, pruritus and stabbing pain, the volunteers are randomly divided into an experimental group and a control group, and 35 volunteers in each group are subjected to a repairing effect test. The volunteers apply the face cream on the face once in the morning and evening according to the requirement of 8 weeks, the experimental group uses the face cream of the sample in the example 3, the control group uses the blank face cream without adding the composition, the corneometer CM825 and the Tewameter TM210 are respectively used for measuring the moisture content of the horny layer of the face skin of the volunteers and the TEWL value of the percutaneous water loss rate before the use and after the use for 2,4,6 and 8 weeks, the higher the moisture content value is, the more the moisture content in the skin is, the TEWL value can reflect the change of the skin barrier function, the smaller the value is, the better the skin barrier is, the better the repairing effect is, the average value of the test data is obtained, and the test result is shown in the table 6. Meanwhile, in the test process, volunteers are asked to score the self-evaluation of the skin improvement condition every week, and the evaluation indexes are as follows: skin moisture, skin softness, rough skin, skin texture, overall soothing satisfaction, soothing scorching satisfaction, relieving desquamation satisfaction and overall improving satisfaction of the skin after use. The scoring criteria were: score 1 indicates very unsatisfactory, score 2 indicates unsatisfactory, score 3 indicates general, score 4 indicates satisfactory, and score 5 indicates very satisfactory. And (3) counting the scoring condition of each group, counting the percentage of the scoring people with the score of more than 3, wherein the higher the percentage of the scoring people with the score of more than 3 is, the higher the improvement satisfaction degree of the corresponding project is, and the test result is shown in a table 7.
TABLE 6 skin moisture content and transdermal Water loss test results
As can be seen from Table 6, in the experimental group, the water content of the skin of the volunteers using the cream to which the composition of the present invention was added was increased by 67.3%, and the TEWL value was decreased by 28.2%, while there was no significant change in the control group. According to the statistical results, the P-value of the moisture content of the stratum corneum and the transdermal water loss rate of the experimental group subjects after using the cream with the added saccharide composition sample were both <0.05, with significant differences.
TABLE 7 volunteer self-evaluation scoring profiles
According to the scoring conditions in the table 7, the number of people with scores of more than 3 who improve the skin is more in the experimental group of the face cream using the composition, and the percentage of the number of people with scores of more than 3 in the control group is lower, which shows that the composition can effectively improve the skin problems of dry face, desquamation, redness, pruritus, stabbing pain and the like. Meanwhile, the self evaluation and satisfaction of volunteers show that the composition has no adverse reaction and good mildness. The above shows that the composition of the invention can increase the water content in the skin and reduce the percutaneous water loss rate, and effectively improve the skin barrier steady state. Therefore, the composition prepared by the invention has obvious repairing effect by comprehensively testing from two aspects of skin barrier repair and skin problem improvement.
In conclusion, the invention has the advantages of good color stability and difficult yellowing after long-time storage, and also has the advantages of good safety and mildness, good anti-wrinkle effect, good repairing effect and the like.
Detailed Description
Example 1: the composition with the anti-wrinkle repair effect and the color change resistance is characterized in that: the composite material consists of the following components in percentage by mass: 40% of saccharide isomer, 25% of ribose, 5% of fructose diphosphate trisodium and 30% of fructo-oligosaccharide solution; the saccharide isomer contains 1% of human milk oligosaccharide, which is 2 '-fucosyllactose (2' -FL).
Example 2: the composition with the anti-wrinkle repairing effect and the color not easy to change is characterized by comprising the following components in parts by weight: the composite material comprises the following components in percentage by mass: 50% of saccharide isomer, 20% of ribose, 2% of fructose diphosphate trisodium and 28% of fructo-oligosaccharide solution; the saccharide isomerate contained 1.5% human milk oligosaccharides, which were a mixture of 2 '-fucosyllactose (2' -FL), 3-fucosyllactose (3-FL), lacto-N-tetraose (LNT), 3 '-sialyllactose (3' -SL), and 6 '-sialyllactose (6' -SL) in any ratio.
Example 3: the composition with the anti-wrinkle repairing effect and the color not easy to change is characterized by comprising the following components in parts by weight: the composite material comprises the following components in percentage by mass: 60% of saccharide isomer, 15% of ribose, 1% of fructose diphosphate trisodium and 24% of fructo-oligosaccharide solution; the saccharide isomerate contains 3% human milk oligosaccharides which are a mixture of 2 '-fucosyllactose (2' -FL), 3 '-sialyllactose (3' -SL) and 6 '-sialyllactose (6' -SL) in any ratio.
Example 4: the composition with the anti-wrinkle repairing effect and the color not easy to change is characterized by comprising the following components in parts by weight: the composite material comprises the following components in percentage by mass: 70% of saccharide isomer, 15% of ribose, 0.5% of fructose diphosphate trisodium and 14.5% of fructo-oligosaccharide solution; the saccharide isomerate contained 3% human milk oligosaccharide, which was 3-fucosyllactose (3-FL).
Example 5: the composition with the anti-wrinkle repairing effect and the color not easy to change is characterized by comprising the following components in parts by weight: the composite material comprises the following components in percentage by mass: 81.8 percent of saccharide isomer, 10 percent of ribose, 0.2 percent of fructose diphosphate trisodium and 8 percent of fructo-oligosaccharide solution; the saccharide isomerate contained 3% of human milk oligosaccharides, which were a mixture of 2 '-fucosyllactose (2' -FL), 3-fucosyllactose (3-FL), lacto-N-tetraose (LNT), 3 '-sialyllactose (3' -SL), and 6 '-sialyllactose (6' -SL) in any ratio.
Claims (3)
1. The composition with the anti-wrinkle repair effect and the color change resistance is characterized in that: the composition consists of the following components: 40% -81.8% of saccharide isomerate, 10% -25% of ribose, 0.2% -5% of fructose diphosphate trisodium and 8% -30% of fructo-oligosaccharide solution; the percentages are mass percentages.
2. The composition with anti-wrinkle repair effect and less prone to discoloration according to claim 1, wherein: the sugar isomer contains more than 1% of human milk oligosaccharide by mass, and the human milk oligosaccharide is one of 2 '-fucosyllactose (2' -FL), 3-fucosyllactose (3-FL), lactose-N-tetraose (LNT), 3 '-sialyllactose (3' -SL) and 6 '-sialyllactose (6' -SL) or a mixture of the 2 '-fucosyllactose (2' -FL), the 3-fucosyllactose (3-FL), the lactosyl-N-tetraose (LNT) and the 3 '-sialyllactose (6' -SL).
3. The composition with anti-wrinkle repair effect and less prone to discoloration according to claim 1, wherein: the fructo-oligosaccharide solution is 35% of aqueous solution of fructo-oligosaccharide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210733199.3A CN115212130A (en) | 2022-06-27 | 2022-06-27 | Composition with anti-wrinkle repair effect and low discoloration possibility |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210733199.3A CN115212130A (en) | 2022-06-27 | 2022-06-27 | Composition with anti-wrinkle repair effect and low discoloration possibility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115212130A true CN115212130A (en) | 2022-10-21 |
Family
ID=83610121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210733199.3A Pending CN115212130A (en) | 2022-06-27 | 2022-06-27 | Composition with anti-wrinkle repair effect and low discoloration possibility |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115212130A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070079367A (en) * | 2006-02-02 | 2007-08-07 | (주)아모레퍼시픽 | Wrinkle treatment cosmetic composition with fructose 1,6-diphosphate trisodium salt |
| KR20190067499A (en) * | 2017-12-07 | 2019-06-17 | 주식회사 한국화장품제조 | Cosmetic composition comprising 3'-Sialyllactose and 6'-Sialyllactose |
| CN110785161A (en) * | 2017-06-23 | 2020-02-11 | 宝洁公司 | Compositions and methods for improving the appearance of skin |
| CN113318005A (en) * | 2021-05-17 | 2021-08-31 | 科丝美诗(中国)化妆品有限公司 | Anti-aging and anti-wrinkle composition and application thereof |
-
2022
- 2022-06-27 CN CN202210733199.3A patent/CN115212130A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070079367A (en) * | 2006-02-02 | 2007-08-07 | (주)아모레퍼시픽 | Wrinkle treatment cosmetic composition with fructose 1,6-diphosphate trisodium salt |
| CN110785161A (en) * | 2017-06-23 | 2020-02-11 | 宝洁公司 | Compositions and methods for improving the appearance of skin |
| KR20190067499A (en) * | 2017-12-07 | 2019-06-17 | 주식회사 한국화장품제조 | Cosmetic composition comprising 3'-Sialyllactose and 6'-Sialyllactose |
| CN113318005A (en) * | 2021-05-17 | 2021-08-31 | 科丝美诗(中国)化妆品有限公司 | Anti-aging and anti-wrinkle composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6248340B1 (en) | Skin care and protection composition and a method for preparation thereof | |
| CN114931530B (en) | Skin care composition with anti-allergy and repairing effects, application thereof, cosmetic and method thereof | |
| CN112494406A (en) | Whitening and freckle-removing cosmetic and preparation method thereof | |
| CN108338965B (en) | Coarse grain composition and preparation method thereof | |
| CN113332227A (en) | Soothing and repairing composition and application thereof in cosmetics | |
| CN113476368B (en) | Relief repair composition and preparation method thereof | |
| CN110693807A (en) | Skin bottom essence and preparation method thereof | |
| CN113018230A (en) | Composition and preparation method and application thereof | |
| CN115607499A (en) | Ginseng and ganoderma lucidum polypeptide composition for resisting wrinkles and tightening and application thereof | |
| CN113520926B (en) | Composition for skin anti-aging, preparation method, cosmetics and application | |
| CN114259453A (en) | Sensitive muscle relieving and repairing spray and preparation method and application thereof | |
| CN108852976B (en) | Crystal moistening nourishing lotion | |
| CN108451892B (en) | Essence with long-acting moisturizing effect and preparation method thereof | |
| CN115212130A (en) | Composition with anti-wrinkle repair effect and low discoloration possibility | |
| CN113975192A (en) | Anti-aging composition and application thereof | |
| CN114073645A (en) | A skin care composition containing mineral components and its preparation method | |
| CN113876604B (en) | Amino acid facial cleanser with high paste forming temperature and preparation method thereof | |
| CN111888275B (en) | Composition and preparation method and application thereof | |
| CN115227633A (en) | Allergy-relieving composition for sensitive skin and application thereof | |
| CN110882192B (en) | Freckle removing stick and preparation method thereof | |
| CN114983917A (en) | Soothing deep moisturizing emulsion and preparation method thereof | |
| US20090274760A1 (en) | Use of An Alkyl Glycoside Or Of A Mixture Of Alkyl Glycosides Having Anti-Ageing And/Or Calming Properties As Active Agents In Cosmetic Compositions, And Methods Of Cosmetic Care Using Said Compositions | |
| CN113208947A (en) | Anti-aging moisturizing composition and application thereof | |
| CN113576934A (en) | Fresh skin-caring and skin-activating essence stock solution and preparation method thereof | |
| CN113384483A (en) | Composition for improving skin elasticity and delaying aging and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221021 |
|
| RJ01 | Rejection of invention patent application after publication |